Understanding the polypharmacological anticancer effects of Xiao Chai Hu tang via a computational pharmacological model

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1777-1783

  Zheng, Chun Song ^a   Wu, Yin Sheng ^a   Bao, Hong Juan ^b   Xu, Xiao Jie ^a,c   Chen, Xing Qiang ^a   Ye, Hong Zhi ^a   Wu, Guang Wen ^a   Xu, Hui Feng ^a   Li, Xi Hai ^a   Chen, Jia Shou ^a   Liu, Xian Xiang ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Xiamen Medical College   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Cancer; Computational pharmacology; Polypharmacology; Xiao Chai Hu tang

Indexed keywords

ANDROGEN RECEPTOR; ANGIOPOIETIN 1 RECEPTOR; AROMATASE; CYCLIN DEPENDENT KINASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; FIBROBLAST COLLAGENASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 4; INOSINATE DEHYDROGENASE; KINESIN SPINDLE PROTEIN; MATRILYSIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; XIAO CHAI HU TANG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CHEMICAL SPACE MAPPING; CLUSTER ANALYSIS; COMPUTATIONAL PHARMACOLOGY; DISEASE ASSOCIATION; GLYCYRRHIZA; MOLECULAR DOCKING; MOLECULAR WEIGHT; PHARMACOLOGICAL PARAMETERS; PHARMACOLOGICAL PROCEDURES; PRINCIPAL COMPONENT ANALYSIS;

EID: 84898432017     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1660     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011.
3. Carney DN and Hansen HH: Non-sm a l l-celllung cancer-stalemate or progress? N Engl J Med 343: 1261-1262, 2000.
4. Bröker LE and Giaccone G: The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 38: 2347-2361, 2002.
5. Yang CS, Wang H and Hu B: Combination of chemopreventive agents in nanoparticles for cancer prevention. Cancer Prev Res (Phila) 6: 1011-1014, 2013.
6. Roth B L, Sheffler DJ and Kroeze WK: Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359, 2004.
7. Xu S, Zhao Y, Zhao YX and Long D: Influence of maintenance therapy of shenyi capsule on survival of advanced non-small cell lung cancer patients after chemotherapy. Journal of Guangzhou University of Traditional Chinese Medicine 30: 337-340, 2013 (In Chinese).
8. Wang CZ, Calway T and Yuan CS: Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med 40: 657-669, 2012.
9. Konkimalla VB and Efferth T: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 116: 207-210, 2008.
10. Li XL and Li HR: Three factors 'toxicity, blood stasis, cold congealing' for pathogenesis exploring of tumor metastasis. China Journal of Traditional Chinese Medicine and Pharmacy 21: 440-441, 2006 (In Chinese).
11. Han GX and Feng JZ: Application of xiao chai hu tang in preventing and treating cancer. Zhejiang Journal of Traditional Chinese Medicine 4: 687-688, 2010 (In Chinese).
12. Liao HF, Lu MC, Chang HC, Wei CC, Kao CH, Chen ZH, Huang CC and Li C: Effects of herbal medicinal formulas on suppressing viral replication and modulating immune responses. Am J Chin Med 38: 173-190, 2010.
13. Li J, Xie M and Gan Y: Effect of Xiaochaihu decoction and different herbal formulation of component on inhibiting H22 liver cancer in mice and enhancing immune function. Zhongguo Zhong Yao Za Zhi 33: 1039-1044, 2008 (In Chinese).
14. Zheng CS, Xu XJ, Ye HZ, Wu GW, Li XH, Huang SP and Liu XX: Computational approaches for exploring the potential synergy and polypharmacology of Duhuo Jisheng Decoction in the therapy of osteoarthritis. Mol Med Rep 7: 1812-1818, 2013.
15. Gu J, Zhang H, Chen L, Xu S, Yuan G and Xu X: Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus. Comput Biol Chem 35: 293-297, 2011.
16. Qiao X, Hou T, Zhang W, Guo S and Xu X: A 3D structure database of components from Chinese traditional medicinal herbs. J Chem Inf Comput Sci 42: 481-489, 2002.
17. Zhou JX, Xie GR and Yang XD (eds): Handbook of the Constituents in Chinese Herb Original Plants. Chemical Industry Press, Beijing, pp1165-1211, 2004 (In Chinese).
18. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, et al: Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40 (Database issue): D1128-D1136, 2012.
19. Venkatachalam CM, Jiang X, Oldfield T and Waldman M: LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 21: 289-307, 2003.
20. Montes M, Braud E, Miteva MA, Goddard ML, Mondésert O, Kolb S, Brun MP, Ducommun B, Garbay C and Villoutreix BO: Receptor-based virual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J Chem Inf Model 48: 157-165, 2008.
21. Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432, 2011.
22. Su G, Kuchinsky A, Morris JH, States DJ and Meng F: GLay: community structure analysis of biological networks. Bioinformatics 26: 3135-3137, 2010.
23. Lipinski CA, Lombardo F, Dominy BW and Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26, 2001.
24. Carmady B and Smith CA: Use of Chinese medicine by cancer patients: a review of surveys. Chin Med 6: 22, 2011.
25. Dobson CM. Chemical space and biology. Nature 432: 824-828, 2004.
26. Sun ML and Zeng BR: Anti-tumor clinical application of Xiaochaihu-tang and the progress of experimental study on its disassembled prescriptions. Hunan Journal of Traditional Chinese Medicine 29(4): 134-136, 2013 (In Chinese).
27. Yang JY, Li YZ, Fan ZW, Zheng SM and Xu JZ: Clinical application overview of Xiaochaihu-tang. Chinese Medicine Modern Distance Education of China 9(9): 74-75, 2011 (In Chinese).
28. Chan JY, Tan BK and Lee SC: Scutellarin sensitizes drug-evoked colon cancer cell apoptosis through enhanced caspase-6 activation. Anticancer Res 29: 3043-3047, 2009.
29. Xu H and Zhang S: Scutellarin-induced apoptosis in HepG2 hepatocellular carcinoma cells via a STAT3 pathway. Phytother Res 27: 1524-1528, 2013.
30. Franek KJ, Zhou Z, Zhang WD and Chen WY: In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Int J Oncol 26: 217-224, 2005.
31. Nagaprashantha LD, Vatsyayan R, Singhal J, Fast S, Roby R, Awasthi S and Singhal SS: Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol 82: 1100-1109, 2011.
32. Ohno H, Araho D, Uesawa Y, Kagaya H, Ishihara M, Sakagami H and Yamamoto M: Evaluation of cytotoxicity and tumorspecificity of licorice flavonoids based on chemical structure. Anticancer Res 33: 3061-3068, 2013.
33. Kinghorn AD, Su BN, Jang DS, Chang LC, Lee D, Gu JQ, Carcache-Blanco EJ, Pawlus AD, Lee SK, Park EJ, et al: Natural inhibitors of carcinogenesis. Planta Med 70: 691-705, 2004.
34. Broxterman HJ and Georgopapadakou NH: Anticancer therapeutics: 'Addictive' targets, multi-targeted drugs, new drug combinations. Drug Resis Updat 8: 183-197, 2005.
35. Shoshan MC and Linder S: Promiscuous and specific anti-cancer drugs: combatting biological complexity with complex therapy. Cancer Ther 2: 297-304, 2004